MCL coexpression mm9:867
From FANTOM5_SSTAR
Phase1 CAGE Peaks
Short description | |
---|---|
Mm9::chr10:61183340..61183369,+ | p2@Aifm2 |
Mm9::chr13:4149879..4149899,- | p1@Akr1c18 |
Mm9::chr16:35652352..35652356,- | p@chr16:35652352..35652356 - |
Mm9::chr17:74573101..74573114,- | p@chr17:74573101..74573114 - |
Mm9::chr18:36446929..36446940,+ | p@chr18:36446929..36446940 + |
Mm9::chr1:89724864..89724867,+ | p@chr1:89724864..89724867 + |
Mm9::chr6:139790173..139790179,+ | p3@Pik3c2g |
Mm9::chr7:107064299..107064302,+ | p@chr7:107064299..107064302 + |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0047006 | 20-alpha-hydroxysteroid dehydrogenase activity | 0.0124180500009131 |
GO:0008208 | C21-steroid hormone catabolic process | 0.0124180500009131 |
GO:0006709 | progesterone catabolic process | 0.0124180500009131 |
GO:0007567 | parturition | 0.0149004353413323 |
GO:0035005 | phosphatidylinositol-4-phosphate 3-kinase activity | 0.0149004353413323 |
GO:0042447 | hormone catabolic process | 0.0159634401118253 |
GO:0042448 | progesterone metabolic process | 0.0159634401118253 |
GO:0031575 | G1/S transition checkpoint | 0.0177269539092413 |
GO:0005662 | DNA replication factor A complex | 0.0177269539092413 |
GO:0006706 | steroid catabolic process | 0.0177269539092413 |
GO:0046332 | SMAD binding | 0.0177269539092413 |
GO:0016303 | 1-phosphatidylinositol-3-kinase activity | 0.0177269539092413 |
GO:0043601 | nuclear replisome | 0.0177269539092413 |
GO:0046854 | phosphoinositide phosphorylation | 0.0177269539092413 |
GO:0030894 | replisome | 0.0177269539092413 |
GO:0035004 | phosphoinositide 3-kinase activity | 0.0177269539092413 |
GO:0005829 | cytosol | 0.0177269539092413 |
GO:0005942 | phosphoinositide 3-kinase complex | 0.0177269539092413 |
GO:0043596 | nuclear replication fork | 0.0177269539092413 |
GO:0016307 | phosphatidylinositol phosphate kinase activity | 0.0177269539092413 |
GO:0046834 | lipid phosphorylation | 0.0177269539092413 |
GO:0007093 | mitotic cell cycle checkpoint | 0.0219921147550164 |
GO:0008207 | C21-steroid hormone metabolic process | 0.0274994885915881 |
GO:0003697 | single-stranded DNA binding | 0.0278947196260274 |
GO:0044255 | cellular lipid metabolic process | 0.0278947196260274 |
GO:0016229 | steroid dehydrogenase activity | 0.0278947196260274 |
GO:0003690 | double-stranded DNA binding | 0.0278947196260274 |
GO:0001727 | lipid kinase activity | 0.0278947196260274 |
GO:0030258 | lipid modification | 0.0294376102880969 |
GO:0005657 | replication fork | 0.0294376102880969 |
GO:0000075 | cell cycle checkpoint | 0.0294376102880969 |
GO:0006629 | lipid metabolic process | 0.0294376102880969 |
GO:0007088 | regulation of mitosis | 0.0294376102880969 |
GO:0044242 | cellular lipid catabolic process | 0.0294376102880969 |
GO:0004428 | inositol or phosphatidylinositol kinase activity | 0.0294376102880969 |
GO:0006915 | apoptosis | 0.0294376102880969 |
GO:0012501 | programmed cell death | 0.0295802256395712 |
GO:0008219 | cell death | 0.0304413879208736 |
GO:0016265 | death | 0.0304413879208736 |
GO:0005737 | cytoplasm | 0.0305063617587466 |
GO:0048522 | positive regulation of cellular process | 0.0365604791767483 |
GO:0048015 | phosphoinositide-mediated signaling | 0.0376593496314086 |
GO:0030384 | phosphoinositide metabolic process | 0.0376593496314086 |
GO:0016491 | oxidoreductase activity | 0.0376593496314086 |
GO:0019867 | outer membrane | 0.0379414103506081 |
GO:0043566 | structure-specific DNA binding | 0.0387239938629354 |
GO:0048518 | positive regulation of biological process | 0.0421566997893442 |
GO:0005625 | soluble fraction | 0.0424979738084686 |
GO:0006650 | glycerophospholipid metabolic process | 0.0437507936601084 |
GO:0050660 | FAD binding | 0.0437507936601084 |
GO:0044454 | nuclear chromosome part | 0.0486768931967854 |
Relative expression of the co-expression cluster over median <br>Analyst:
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>
Ontology term | p-value | n |
---|
Ontology term | p-value | n |
---|
Ontology term | p-value | n |
---|
TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
{{{tfbs_overrepresentation_jaspar}}} |